A comprehensive multicenter study recently published in The Journal of Clinical Endocrinology & Metabolism has uncovered a significant gender-based disparity in the effectiveness of growth-promoting therapies for children with classical congenital adrenal hyperplasia (CAH). The research, which analyzed long-term outcomes for patients with the most common form of the condition, suggests that while hormonal interventions successfully preserve adult height in boys, they often fail to provide comparable benefits for girls. This finding challenges long-standing clinical assumptions and underscores the urgent need for more personalized, sex-specific treatment protocols in pediatric endocrinology.
The Clinical Landscape of Classical Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia refers to a group of rare, autosomal recessive genetic disorders characterized by defects in the enzymatic pathways of cortisol biosynthesis in the adrenal glands. The vast majority of cases—approximately 95%—are caused by a deficiency in the 21-hydroxylase enzyme (21-OHD). The adrenal glands, situated atop the kidneys, are responsible for producing several vital hormones, including cortisol, which helps the body respond to stress and maintain blood glucose; aldosterone, which regulates salt and water balance; and androgens, which are male sex hormones.
In classical 21-OHD, the genetic mutation is severe enough to virtually eliminate the production of cortisol and, in many cases, aldosterone. This deficiency triggers a physiological feedback loop: the pituitary gland, sensing low cortisol levels, releases excessive amounts of adrenocorticotropic hormone (ACTH) to stimulate the adrenal glands. However, because the enzymatic pathway to cortisol is blocked, the glands instead produce an overabundance of androgen precursors.
This hormonal "flood" of androgens has devastating effects on growth and development. In female infants, it can lead to ambiguous genitalia at birth. In both sexes, the excess androgens cause rapid linear growth during early childhood, but they also trigger the premature maturation of the skeleton. This leads to the early fusion of the epiphyseal plates (growth plates), resulting in a paradox where children are tall for their age but ultimately end up as significantly shorter-than-average adults.
Study Methodology and Patient Cohort
The study, titled "Impact of Growth-promoting Therapies on Puberty, Growth, and Final Height in Classical 21-hydroxylase Deficiency," was a retrospective, longitudinal investigation led by researchers from the pediatric endocrinology departments at Marmara University and Istanbul University in Türkiye. This research team is uniquely positioned to study CAH due to the relatively higher prevalence of the condition in certain Mediterranean populations, providing a robust data set for analysis.
The researchers tracked a total of 284 patients with genetically confirmed classical 21-OHD. Crucially, these patients were diagnosed before the widespread implementation of national newborn screening programs, meaning their clinical progression reflects the "natural" course of the disease managed under traditional medical oversight. The study aimed to evaluate how growth-promoting therapies (GPT) influenced final adult height (FAH) relative to the patients’ genetic potential, known as mid-parental height (MPH).
Of the total cohort, 41.1% of the patients received some form of growth-promoting intervention. These therapies were typically introduced when clinicians observed signs of precocious puberty or advanced bone age that threatened the child’s predicted adult height.
The Gender Disparity in Height Outcomes
The most striking finding of the study was the divergence in outcomes between male and female patients. Pediatric endocrinologists use the "height gap"—the difference between the patient’s final adult height and their mid-parental height—as a primary measure of treatment success.
In boys, the use of growth-promoting therapies was associated with a marked improvement in height outcomes. Boys who received these treatments saw their height deficit shrink from -6.7 cm (relative to their genetic potential) to -2.3 cm. This suggests that the interventions were highly effective at slowing bone maturation and allowing for a longer duration of growth.
In contrast, the data for girls told a different story. Girls who underwent the same categories of growth-promoting protocols did not see an improvement in their final height outcomes. In fact, their height deficit relative to their genetic potential moved from -3.7 cm to -6.6 cm. The researchers noted that this lack of benefit in girls is a critical area for further investigation, suggesting that the physiological response to these drugs may be mediated by sex-specific hormonal environments.
The Mechanics of Growth-Promoting Interventions
To understand why these differences exist, it is necessary to examine the specific drugs used in growth-promoting protocols. The study focused on three primary types of medication:
- Gonadotropin-Releasing Hormone (GnRH) Analogs: These drugs are used to treat central precocious puberty. By suppressing the signals that tell the body to begin puberty, they delay the onset of the pubertal growth spurt and, more importantly, the subsequent closure of the growth plates.
- Aromatase Inhibitors (AIs): These medications block the conversion of androgens into estrogens. In both boys and girls, estrogen is the primary hormone responsible for the fusion of the epiphyseal plates. By lowering estrogen levels, AIs aim to extend the window of time available for linear growth.
- Cyproterone Acetate: An anti-androgen that competes with androgens at the receptor level, helping to mitigate the effects of the androgen excess characteristic of CAH.
The research team hypothesized that the superior outcomes in boys might be specifically linked to the use of aromatase inhibitors. In males, blocking the conversion of testosterone to estrogen is a highly effective way to delay bone age without significantly disrupting other developmental processes. In females, however, the hormonal balance is more delicate, as estrogen plays a more central role in overall development, and the suppression of estrogen may have different systemic effects that negate the potential height benefits.
The Puberty Paradox in CAH Patients
Beyond height outcomes, the study provided a detailed look at how classical 21-OHD alters the trajectory of puberty. The researchers found that puberty in these patients follows an atypical pattern that is often difficult for clinicians to manage.
The data revealed that while CAH patients often enter puberty earlier than their peers—a result of the long-term exposure to adrenal androgens—the "tempo" of their puberty is significantly slower. This means that once puberty begins, it lasts much longer than it does in the general population. This prolonged pubertal window was especially evident in female patients.
While a longer puberty might theoretically provide more time for growth, the study found that this period is often characterized by fluctuating hormonal levels and the need for frequent adjustments in medication. The extended duration of treatment exposure may also increase the risk of side effects from glucocorticoids, which are the cornerstone of CAH management but are known to inhibit growth when administered in high doses.
The Glucocorticoid "Tightrope"
A recurring theme in the study’s analysis is the extreme difficulty physicians face when balancing medication doses. The primary treatment for CAH is glucocorticoid replacement (such as hydrocortisone), which serves two purposes: it replaces the cortisol the body cannot make, and it suppresses the overproduction of ACTH and adrenal androgens.
However, glucocorticoid therapy is a double-edged sword. If the dose is too low (under-treatment), the excess adrenal androgens will continue to accelerate bone maturation and cause early growth plate fusion. If the dose is too high (over-treatment), the glucocorticoids themselves will directly stunt linear growth and cause other complications, such as weight gain and bone density loss.
The researchers emphasized that the "therapeutic window" for optimal growth is incredibly narrow. The fact that girls in the study did not benefit from growth-promoting therapies may suggest that they are more sensitive to the growth-inhibiting effects of glucocorticoids, or that their androgen levels are more difficult to suppress without resorting to doses that compromise height.
Recommendations for Personalized Care
In light of these findings, the study’s authors have called for a paradigm shift in how growth is managed in children with classical 21-OHD. They argue that the "one-size-fits-all" approach to growth-promoting therapies is no longer tenable.
The investigators recommend that clinicians implement highly personalized pubertal monitoring protocols. For girls, in particular, the decision to initiate growth-promoting therapies should be made with extreme caution. Decisions should be based on a comprehensive assessment of:
- Baseline height prognosis: A realistic assessment of the child’s height potential based on parental heights and current bone age.
- Pubertal progression: Close monitoring of the tempo of puberty, rather than just the age of onset.
- Treatment response: Frequent evaluations to determine if the therapies are actually slowing bone maturation without causing adverse effects.
Implications for Future Research and Clinical Practice
The study from Türkiye serves as a significant milestone in the understanding of CAH management. By highlighting the sex-dependent differences in treatment outcomes, it opens new avenues for research into the molecular mechanisms of growth plate fusion and the sex-specific effects of aromatase inhibitors.
Medical experts suggest that the next step in this field will likely involve the use of newer, more targeted therapies. For instance, several pharmaceutical companies are currently developing ACTH antagonists and CRH (corticotropin-releasing hormone) antagonists. These drugs aim to reduce adrenal androgen production at the source, potentially allowing for lower doses of glucocorticoids and reducing the need for secondary growth-promoting drugs.
Furthermore, the study highlights the importance of early diagnosis. While the cohort in this study was diagnosed before newborn screening, modern screening programs allow for immediate treatment from birth. Future studies will be needed to determine if the gender gap in growth outcomes persists when treatment begins in the first days of life.
In conclusion, while growth-promoting therapies offer a valuable tool for improving the adult height of boys with classical congenital adrenal hyperplasia, their efficacy in girls remains unproven and potentially counterproductive. The findings published in The Journal of Clinical Endocrinology & Metabolism mandate a more nuanced and individualized approach to pediatric CAH care, ensuring that every child—regardless of sex—has the best possible chance to reach their full genetic growth potential.
